Try the modernized beta website. Learn more about the modernization effort.
Working… Menu
Trial record 1 of 1 for:    DRM06-AD06
Previous Study | Return to List | Next Study

Safety and Efficacy of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroid in Moderate-to-Severe Atopic Dermatitis. (ADhere)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04250337
Recruitment Status : Completed
First Posted : January 31, 2020
Last Update Posted : October 20, 2021
Dermira, Inc.
Information provided by (Responsible Party):
Eli Lilly and Company

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : August 11, 2021
Actual Study Completion Date : September 16, 2021